A phase 1/2 study of oral infliximab in patients with inflammatory bowel disease (IBD)
Latest Information Update: 02 Sep 2020
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
- 02 Sep 2020 New trial record
- 20 Aug 2020 According to an Intract Pharma media release, the UK regulatory body, MHRA, has cleared to proceed this phase 1/2 study in oral infliximab in the second half of 2021. The company has collaborated with the Celltrion Group for the development of this oral Infliximab.